RNAC
Cartesian Therapeutics Inc.
7.90$
-1.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -417.3% | -373.7% | -243.5% | -25,138.6% | -6,551.6% | -770.3% | 210.2% | -71.0% | -28.6% | -196.7% | -60.8% | -2,643.6% | |
| 28.4% | 17.4% | 9.9% | 362.3% | 108.0% | 30.4% | 4.4% | 1.5% | 1.2% | 3.2% | 3.0% | 105.8% | |
| 40.3% | 18.7% | 25.4% | 1,971.5% | 632.8% | 77.3% | 32.7% | 9.1% | 10.1% | 86.6% | 16.9% | 376.2% | |
| 46.6% | 20.6% | 31.2% | 2,615.0% | 662.3% | 95.4% | 101.8% | 13.0% | -8.0% | – | – | – | |
| -68.7% | 7.1% | 163.3% | 3,440.1% | -86.5% | -67.1% | 512.2% | -56.6% | -54.5% | 19.1% | -14.9% | -288.3% | |
| 7.5% | 19.3% | 7.2% | 354.1% | 97.9% | 0.7% | 4.9% | 1.3% | 1.1% | 0.8% | 23.4% | 195.0% | |
| -7.5% | -77.8% | -273.4% | -1,013.5% | 2,798.7% | 3.4% | -4.5% | -20.1% | -13.5% | 133.1% | -22.5% | -195.0% | |
| – | – | 56.5% | 12,295.2% | – | 0.4% | 1.1% | – | – | – | – | – | |
| 4.5% | 545.3% | 887.8% | 87.0% | 21.7% | 0.4% | 1.1% | 0.2% | 0.2% | -23.7% | 0.0% | – | |
| 147.8% | 190.2% | 99.3% | 3,875.8% | -310.1% | -41.9% | 6.3% | 0.0% | 0.0% | -105.6% | 0.0% | – | |
| 814.8% | 730.4% | 837.1% | 31,895.2% | 77.2% | 1,573.2% | 86.9% | 62.2% | 35.4% | -50.5% | 432.8% | -288.0% | |
| 280.8% | 278.9% | 320.1% | 5,779.7% | -3,687.2% | 790.3% | 292.3% | -28.9% | -6.7% | -114.4% | 349.5% | -3,125.0% | |
| -424.8% | -393.0% | -250.8% | -25,492.8% | -6,649.5% | -771.0% | 205.3% | -72.2% | -29.6% | -197.5% | -84.2% | -2,838.6% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.